Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial.
group B streptococcus
immunogenicity
maternal immunization
safety
second dose
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
10 06 2020
10 06 2020
Historique:
received:
28
02
2019
accepted:
09
08
2019
pubmed:
9
8
2019
medline:
7
1
2021
entrez:
9
8
2019
Statut:
ppublish
Résumé
Maternal immunization against group B streptococcus (GBS) could protect infants from invasive GBS disease. Additional doses in subsequent pregnancies may be needed. We evaluated the safety and immunogenicity of a second dose of an investigational trivalent CRM197-glycoconjugate GBS vaccine (targeting serotypes Ia/Ib/III), administered to nonpregnant women 4-6 years postdose 1. Healthy women either previously vaccinated with 1 dose of trivalent GBS vaccine 4-6 years before enrollment (n = 53) or never GBS vaccinated (n = 27) received a single trivalent GBS vaccine injection. Adverse events (AEs) were recorded. Serotype-specific (Ia/Ib/III) anti-GBS antibodies were measured by multiplex immunoassay prevaccination and 30/60 days postvaccination. AEs were reported with similar rates after a first or second dose; none were serious. Of previously GBS-vaccinated women, 92%-98% had anti-GBS concentrations that exceeded an arbitrary threshold (8 µg/mL) for each serotype 60 days postdose 2 vs 36%-56% postdose 1 in previously non-GBS-vaccinated women. Of previously GBS-vaccinated women with undetectable baseline (predose 1) anti-GBS levels, 90%-98% reached this threshold postdose 2. For each serotype, anti-GBS geometric mean concentrations (GMCs) 30/60 days postdose 2 in previously GBS-vaccinated women were ≥200-fold higher than baseline GMCs. Among women with undetectable baseline anti-GBS levels, postdose 2 GMCs in previously GBS-vaccinated women exceeded postdose 1 GMCs in previously non-GBS-vaccinated women (≥7-fold). A second trivalent GBS vaccine dose administered 4-6 years postdose 1 was immunogenic with a favorable safety profile. Women with undetectable preexisting anti-GBS concentrations may benefit from a sufficiently spaced second vaccine dose. NCT02690181.
Sections du résumé
BACKGROUND
Maternal immunization against group B streptococcus (GBS) could protect infants from invasive GBS disease. Additional doses in subsequent pregnancies may be needed. We evaluated the safety and immunogenicity of a second dose of an investigational trivalent CRM197-glycoconjugate GBS vaccine (targeting serotypes Ia/Ib/III), administered to nonpregnant women 4-6 years postdose 1.
METHODS
Healthy women either previously vaccinated with 1 dose of trivalent GBS vaccine 4-6 years before enrollment (n = 53) or never GBS vaccinated (n = 27) received a single trivalent GBS vaccine injection. Adverse events (AEs) were recorded. Serotype-specific (Ia/Ib/III) anti-GBS antibodies were measured by multiplex immunoassay prevaccination and 30/60 days postvaccination.
RESULTS
AEs were reported with similar rates after a first or second dose; none were serious. Of previously GBS-vaccinated women, 92%-98% had anti-GBS concentrations that exceeded an arbitrary threshold (8 µg/mL) for each serotype 60 days postdose 2 vs 36%-56% postdose 1 in previously non-GBS-vaccinated women. Of previously GBS-vaccinated women with undetectable baseline (predose 1) anti-GBS levels, 90%-98% reached this threshold postdose 2. For each serotype, anti-GBS geometric mean concentrations (GMCs) 30/60 days postdose 2 in previously GBS-vaccinated women were ≥200-fold higher than baseline GMCs. Among women with undetectable baseline anti-GBS levels, postdose 2 GMCs in previously GBS-vaccinated women exceeded postdose 1 GMCs in previously non-GBS-vaccinated women (≥7-fold).
CONCLUSIONS
A second trivalent GBS vaccine dose administered 4-6 years postdose 1 was immunogenic with a favorable safety profile. Women with undetectable preexisting anti-GBS concentrations may benefit from a sufficiently spaced second vaccine dose.
CLINICAL TRIALS REGISTRATION
NCT02690181.
Identifiants
pubmed: 31394574
pii: 5545276
doi: 10.1093/cid/ciz737
pmc: PMC7286364
doi:
Substances chimiques
Antibodies, Bacterial
0
Streptococcal Vaccines
0
Vaccines, Conjugate
0
Banques de données
ClinicalTrials.gov
['NCT02690181']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2570-2579Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Infect Dis. 2001 Oct 15;184(8):1022-8
pubmed: 11574917
Vaccine. 2017 Jun 5;35(25):3286-3294
pubmed: 28487056
J Infect. 2018 May;76(5):449-456
pubmed: 29374589
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S125-S132
pubmed: 29117322
Lancet Infect Dis. 2016 May;16(5):546-555
pubmed: 26869376
Vaccine. 2013 Aug 28;31 Suppl 4:D20-6
pubmed: 23219695
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S133-S142
pubmed: 29117329
Vaccine. 2016 Jun 3;34(26):2876-2879
pubmed: 26988258
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S160-S172
pubmed: 29117326
Expert Rev Vaccines. 2018 Jul;17(7):635-651
pubmed: 29961350
Lancet. 2012 Feb 11;379(9815):547-56
pubmed: 22226047
Vaccine. 2015 Nov 27;33(48):6793-9
pubmed: 26478200
mSphere. 2019 Aug 7;4(4):
pubmed: 31391276
Infect Immun. 2001 Nov;69(11):6696-701
pubmed: 11598040
N Engl J Med. 1976 Apr 1;294(14):753-6
pubmed: 768760
Obstet Gynecol. 2013 Jul;122(1):64-71
pubmed: 23743455
Vaccine. 2016 Apr 4;34(15):1786-91
pubmed: 26928074
Vaccine. 2003 Jun 2;21(19-20):2573-9
pubmed: 12744893
Lancet Infect Dis. 2016 Aug;16(8):923-34
pubmed: 27139805
Curr Opin Infect Dis. 2016 Jun;29(3):262-7
pubmed: 26926474
J Infect Dis. 2014 Mar 1;209(5):781-8
pubmed: 24133184
Pediatrics. 1981 Oct;68(4):544-9
pubmed: 7033911
Vaccine. 2008 Jun 19;26(26):3209-22
pubmed: 18462843
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S100-S111
pubmed: 29117327
F1000Res. 2016 Sep 22;5:2355
pubmed: 27803803
BJOG. 2016 Apr;123(5):730-7
pubmed: 26399217
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S143-S151
pubmed: 29117324
Expert Rev Vaccines. 2015 Jan;14(1):135-49
pubmed: 25242617
J Infect Dis. 2004 Sep 1;190(5):928-34
pubmed: 15295698
Obstet Gynecol. 2016 Feb;127(2):213-21
pubmed: 26942345
Clin Infect Dis. 2017 Nov 6;65(suppl_2):S200-S219
pubmed: 29117332
Clin Infect Dis. 2017 Nov 13;65(11):1897-1904
pubmed: 29029127